Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Impact · against what's priced in

The collaboration provides a concrete catalyst for SMMT by validating the expanded indication potential (TNBC) that the market currently refuses to pay for. For AZN and 4568, the news is marginally positive but lacks the context of their current price assumptions to determine if it is a significant driver.

SMMT+0.30: Challenges what's priced in
The price assumes

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

What matters in this story

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

What matters in this story

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

How each ticker is affected

Connected tickers

Track these names every morning.

Nasdaq Scores Record High As Oil Falls; Nvidia Hits New Highs

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

What matters in this story

Next reads from the same story arc

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

What matters in this story

Next reads from the same story arc

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

How each ticker is affected

Connected tickers

Track these names every morning.

Nasdaq Scores Record High As Oil Falls; Nvidia Hits New Highs

Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight